Approval · Notice of Compliance 28647 · 2022
AZARGA: Notice of Compliance 28647
Issued July 19, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28647
- Date
- July 19, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- .To update the Product Monograph to the current 2020 PM Master Template and to update the carton labels to include the expiry date and lot number in the 2D matrix code format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AZARGA | Not yet assigned | — |
Medicinal ingredients
- TIMOLOL MALEATE 0.5 PER
- BRINZOLAMIDE 1 PER